Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Filings indexed 2,815 across all filing types
Latest filing 2025-11-12 Foreign Filer Report
Country DK Denmark
Listing CO GMAB

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2025-11-12 English
6-K
Foreign Filer Report
2025-11-06 English
SC TO-T/A Filing
Regulatory Filings
2025-10-31 English
SC TO-T Filing
Regulatory Filings
2025-10-21 English
6-K
Foreign Filer Report
2025-10-17 English
Earnings Release 2025
Earnings Release Classification · 1% confidence The document is a short company announcement (under 5,000 characters) detailing specific financial highlights (net sales of DARZALEX) for a quarterly period. It functions as an initial release of key financial data rather than a full quarterly report or a comprehensive earnings call transcript. According to the 'Menu vs Meal' rule, this is an Earnings Release (ER). Q3 2025
2025-10-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.